Apixaban: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), G-BA (Germany) and HAS (France), among others, recommended or restricted apixaban, while CONITEC (Brazil) did not recommend it.
The file has been open for more than a decade: 15 years separate the first record, 4 Mar 2011 at AWMSG (Wales), from the most recent, 24 Mar 2026 at AOTMIT (Poland).
TLV (Sweden) changed its position: restricted on 13 Dec 2011, recommended by 5 Jun 2013.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
The file is active: 6 of 31 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for apixaban by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 31 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess apixaban, on 4 Mar 2011; AOTMIT (Poland) did not open a file until 23 Feb 2026 — an unusually long tail of 14.9 years between the earliest and latest system to look at it.
The record arrives in waves: 9 separate years each carry two or more decisions, spread across 10 years in total.
8 of the 11 agencies here assessed apixaban more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for apixaban.
The full ledger for apixaban reads 16 recommended, 6 other, 4 restricted and 2 deferred to NICE, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 24 Mar 2026 | Apixaban Adamed reimbursement recommendation | recommended conditionally | source |
| HAS (France) | 23 Apr 2025 | Indication extension | SMR substantial · ASMR V | source |
| PHARMAC (New Zealand) | 16 Mar 2016 | Prevention of venous thromboembolic events following major orthopaedic surgery | PTAC advice: No Formal Recommendation · decision reached | source |
| CONITEC (Brazil) | 10 Feb 2016 | Fibrilação atrial Não valvar | not incorporated | source |
| PBAC (Australia) | 2015 | Deep vein thrombosis and pulmonary embolism | The PBAC recommended the listing of apixaban for the treatment of deep vein thrombosis and… | source |
26 further decisions for apixaban, across 9 agencies, are not shown here. They include the most recent record on file, 24 Mar 2026 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 21 further source documents.
Related molecules
- rivaroxaban — same ATC class B01A — Antithrombotics
- enoxaparin — same ATC class B01A — Antithrombotics
- dabigatran — same ATC class B01A — Antithrombotics
- fondaparinux — same ATC class B01A — Antithrombotics
- ticagrelor — same ATC class B01A — Antithrombotics
- clopidogrel — same ATC class B01A — Antithrombotics
Coverage: 31 decisions for apixaban from 11 agencies, 2011 to 2026. Data to 7 Sep 2026. ATC class B01A — Antithrombotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.